Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan in Early and Intermediate Age-related Macular Degeneration
NCT05230537Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2022
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of Iptacopan in age-related macular degeneration (AMD), sponsored by Novartis. Started Feb 2022; status: completed.
02
Drugs
Iptacopan
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT05230537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05230537.